Literature DB >> 14687775

Demographic, pathologic, and toxicological profiles of 127 decedents testing positive for ephedrine alkaloids.

Keith M Blechman1, Steven B Karch, Boyd G Stephens.   

Abstract

The relative toxicity of ephedra-containing dietary supplements is disputed. In order to ascertain the magnitude of the problem, we reviewed all autopsies in our Medical Examiner's jurisdiction, from 1994 to 2001, where ephedrine or any its isomers (E+) were detected. Toxicology testing results were tabulated and anatomic findings in E+ cases were compared to those in a control group of drug-free trauma victims. Of 127 E+ cases identified, 33 were due to trauma. Decedents were mostly male (80.3%) and mostly Caucasian (59%). Blood ephedrine concentrations were <0.49 mg/l in 50% of the cases, range 0.07-11.73 mg/l in trauma victims, and 0.02-12.35 mg/l in non-trauma cases. Norephedrine (NE) was present in the blood of 22.8% (mean of 1.81 mg/l, S.D.=3.14 mg/l) and in the urine of 36.2% (mean of 15.6 mg/l, S.D.=21.50mg/l). Pseudoephedrine (PE) was present in the blood of 6.3% (8/127). More than 88% (113/127) of the decedents also tested positive for other drugs, the most common being cocaine (or its metabolites) and morphine. The most frequent pathologic diagnoses were hepatic steatosis (27/127) and nephrosclerosis (22/127). Left ventricular hypertrophy was common, and coronary artery disease (CAD) detected in nearly one third of the cases. The most common findings in E+ deaths are those generally associated with chronic stimulant abuse, and abuse of other drugs was common in those with CAD. There were no cases of heat stroke or rhabdomyolysis. In most cases, norephedrine was not detected, suggesting it plays no role in ephedrine toxicity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14687775     DOI: 10.1016/j.forsciint.2003.09.012

Source DB:  PubMed          Journal:  Forensic Sci Int        ISSN: 0379-0738            Impact factor:   2.395


  3 in total

1.  Ephedra-Induced Gastric Mucosal Injury.

Authors:  Joseph B Lillegard; John R Porterfield
Journal:  Case Rep Gastroenterol       Date:  2010-02-27

2.  Antitussive, anti-pyretic and toxicological evaluation of Ma-Xing-Gan-Shi-Tang in rodents.

Authors:  Yu-Chin Lin; Ching-Wen Chang; Chi-Rei Wu
Journal:  BMC Complement Altern Med       Date:  2016-11-10       Impact factor: 3.659

3.  New Therapeutic Insight into the Effect of Ma Huang Tang on Blood Pressure and Renal Dysfunction in the L-NAME-Induced Hypertension.

Authors:  Mi Hyeon Hong; Hye Yoom Kim; Youn Jae Jang; Se Won Na; Byung Hyuk Han; Jung Joo Yoon; Chang Seob Seo; Ho Sub Lee; Yun Jung Lee; Dae Gill Kang
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-13       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.